Lipid-Related Markers and Cardiovascular Disease Prediction

This large analysis asked a deliberately stringent question: does adding fancier lipid markers — apoB and apoA1, lipoprotein(a), or Lp-PLA2 — to a standard cholesterol-based risk score actually improve prediction enough to matter in the general population?

The answer was largely no. Replacing total and HDL cholesterol with apoB and apoA1 did not improve risk discrimination. Adding any of the extra markers produced statistically significant but vanishingly small gains in the C-index, and reclassified less than 1 percent of people into a different risk category. For population-wide screening, the added markers did not earn their cost.

This is the counterweight to the apoB and Lp(a) enthusiasm elsewhere in this library, and it must be read carefully. Its conclusion concerns unselected population screening by statistical discrimination — a high bar that few single markers clear. It does not address the targeted use of Lp(a) or apoB in specific patients (those with discordance, family history, or premature disease), where the clinical value lies.

We rate the evidence very strong methodologically, but note its low clinical-significance score reflects a genuinely modest practical payoff for routine population use. It is a rigorous reminder that improving a risk equation is hard, and that marker enthusiasm should be aimed where it helps most.